These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16225367)

  • 21. Are there any antirheumatic drugs that modify the course of ankylosing spondylitis?
    Laurent R
    Baillieres Clin Rheumatol; 1990 Aug; 4(2):387-400. PubMed ID: 1674450
    [No Abstract]   [Full Text] [Related]  

  • 22. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Wang S; He Q; Shuai Z
    Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
    Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
    Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials.
    Migliore A; Broccoli S; Bizzi E; Laganà B
    J Med Econ; 2012; 15(3):473-80. PubMed ID: 22335398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis.
    Migliore A; Bizzi E; Bernardi M; Picchianti Diamanti A; Laganà B; Petrella L
    Clin Drug Investig; 2015 Jan; 35(1):23-9. PubMed ID: 25388909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial.
    Santra G; Sarkar RN; Phaujdar S; Banerjee S; Siddhanta S
    Singapore Med J; 2010 Nov; 51(11):883-7. PubMed ID: 21140116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ankylosing spondylitis].
    El Maghraoui A
    Presse Med; 2004 Nov; 33(20):1459-64. PubMed ID: 15611681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis.
    Escalas C; Trijau S; Dougados M
    Rheumatology (Oxford); 2010 Jul; 49(7):1317-25. PubMed ID: 20360041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current therapeutics for spondyloarthritis.
    Toussirot É
    Expert Opin Pharmacother; 2011 Nov; 12(16):2469-77. PubMed ID: 21988214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
    Braun J; van der Horst-Bruinsma IE; Huang F; Burgos-Vargas R; Vlahos B; Koenig AS; Freundlich B
    Arthritis Rheum; 2011 Jun; 63(6):1543-51. PubMed ID: 21630245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy.
    Hammoudeh M; Zack DJ; Li W; Stewart VM; Koenig AS
    J Int Med Res; 2013 Aug; 41(4):1150-9. PubMed ID: 23803306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The treatment of ankylosing spondylitis.
    Scalapino KJ; Davis JC
    Clin Exp Med; 2003 Feb; 2(4):159-65. PubMed ID: 12624705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of ankylosing spondylitis and other spondyloarthritides.
    Braun J; Baraliakos X
    Curr Opin Rheumatol; 2009 Jul; 21(4):324-34. PubMed ID: 19461519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of sulfasalazine in ankylosing spondylitis.
    Ferraz MB; Tugwell P; Goldsmith CH; Atra E
    J Rheumatol; 1990 Nov; 17(11):1482-6. PubMed ID: 1980310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indirect comparison of anti-TNF-α agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials.
    Shu T; Chen GH; Rong L; Feng F; Yang B; Chen R; Wang J
    Clin Exp Rheumatol; 2013; 31(5):717-22. PubMed ID: 23899710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.
    Zochling J; van der Heijde D; Dougados M; Braun J
    Ann Rheum Dis; 2006 Apr; 65(4):423-32. PubMed ID: 16126792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect.
    Corkill MM; Jobanputra P; Gibson T; Macfarlane DG
    Br J Rheumatol; 1990 Feb; 29(1):41-5. PubMed ID: 1968354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Overview of Adalimumab Therapy for Ankylosing Spondylitis.
    Sukhanova AM; Gilavian MA; Melnik EV; Shikh EV; Petukhov AE; Gegechkori VI; Dementev SP; Vlasov AM; Ramenskaya GV
    Curr Rheumatol Rev; 2024; 20(5):501-513. PubMed ID: 38415452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.